These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 886191)

  • 1. Immunosuppression of experimental autoimmune myasthenia gravis by azathioprine. II. Evaluation of immunological mechanism.
    Tarrab-Hazdai R; Abramsky O; Fuchs S
    J Immunol; 1977 Aug; 119(2):702-6. PubMed ID: 886191
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunochemical analysis of acetylcholine receptor and its relevance to specific treatment of experimental autoimmune myasthenia gravis.
    Fuchs S
    Adv Cytopharmacol; 1979; 3():279-85. PubMed ID: 382790
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunosuppression of experimental autoimmune myasthenia gravis by hydrocortisone and azathioprine.
    Abramsky O; Tarrab-Hazdai R; Aharonov A; Fuchs S
    J Immunol; 1976 Jul; 117(1):225-8. PubMed ID: 932425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunosuppressive therapy of various autoimmune diseases of the nervous system].
    Neretin VIa; Odinokova VA; Kir'iakov VA; Sapfirova VA
    Sov Med; 1990; (12):31-5. PubMed ID: 2097756
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune regulation of experimental myasthenia.
    Fuchs S; Bartfeld D; Eshhar Z; Feingold C; Mochly-Rosen D; Novick D; Schwartz M; Tarrab-Hazdai R
    J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):634-43. PubMed ID: 7400824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic control of experimental autoimmune myasthenia gravis in mice. II. Lymphocyte proliferative response to acetylcholine receptor is dependent on Lyt-1+23- cells.
    Christadoss P; Krco CJ; Lennon VA; David CS
    J Immunol; 1981 Apr; 126(4):1646-7. PubMed ID: 7204982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunopharmacological treatment in myasthenia gravis.
    Nyberg-Hansen R; Gjerstad L
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):201-10. PubMed ID: 3289206
    [No Abstract]   [Full Text] [Related]  

  • 8. Lymphocyte activation in experimental autoimmune myasthenia gravis.
    De Baets MH; Einarson B; Lindstrom JM; Weigle WO
    J Immunol; 1982 May; 128(5):2228-35. PubMed ID: 6977589
    [No Abstract]   [Full Text] [Related]  

  • 9. Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis.
    Goulon M; Elkharrat D; Lokiec F; Gajdos P
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):211-7. PubMed ID: 3260050
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experimental rabbit model of myasthenia gravis produced with acetylcholine receptor of nicotinic type from the "generating organ" of electric ray (author's transl)].
    Tu LH
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Feb; 14(1):16-8. PubMed ID: 7307781
    [No Abstract]   [Full Text] [Related]  

  • 11. Myasthenia gravis.
    Newsom-Davis J
    Ann Ital Med Int; 1988; 3 Suppl 1():32-7. PubMed ID: 3152864
    [No Abstract]   [Full Text] [Related]  

  • 12. Scientific overview of myasthenia gravis and an assessment of the role of plasmapheresis.
    Tindall RS
    Prog Clin Biol Res; 1982; 106():113-42. PubMed ID: 6757936
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunologic aspects of the pathogenesis of myasthenia (review)].
    Gekht BM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1968; 68(4):616-20. PubMed ID: 4879953
    [No Abstract]   [Full Text] [Related]  

  • 14. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis.
    Shenoy M; Baron S; Wu B; Goluszko E; Christadoss P
    J Immunol; 1995 Jun; 154(11):6203-8. PubMed ID: 7751658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myasthenia gravis in newborn infants--pathological mechanism, clinical symptomatology and therapeutic procedures].
    Krauze M; Musialik E; Swietliński J; Litwa K; Latko E; Górny J; Sobczyk J
    Wiad Lek; 1992 Aug; 45(15-16):610-4. PubMed ID: 1488831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive treatment for juvenile myasthenia gravis.
    Badurska B; Ryniewicz B; Strugalska H
    Eur J Pediatr; 1992 Mar; 151(3):215-7. PubMed ID: 1601015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myasthenia gravis and acetylcholine receptor].
    Abramsky O; Aharonov A; Tarrab-Hazdai R; Fuchs S
    Harefuah; 1975 Dec; 89(12):553-6. PubMed ID: 815144
    [No Abstract]   [Full Text] [Related]  

  • 18. Autoimmune aspects of myasthenia gravis.
    Lisak RP; Levinson AI; Zweiman B
    Concepts Immunopathol; 1985; 2():65-101. PubMed ID: 3916415
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of alpha-bungarotoxin binding to acetylcholine receptors by antisera from animals with experimental autoimmune myasthenia gravis.
    Claudio T; Raftery MA
    J Supramol Struct; 1980; 14(3):267-79. PubMed ID: 6971372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG; Duan RS; Zhu WH; Lu CZ
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.